Adaptive Highlights MRD Testing in New Myeloma Cure Definition
SEATTLE — September 25, 2026 Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma presented at...
Hematology
Advertisement
PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
Adaptive Highlights Updated NCCN MRD Guidance in Multiple Myeloma
SEATTLE, Wash. — September 17, 2026 Adaptive Biotechnologies highlighted updates to the National Comprehensive Cancer Network (NCCN) Guidelines for...
Akeso AK158D1 Gets NMPA Phase I Clearance for Tumors
Hong Kong, September 17, 2026 Akeso, Inc. has announced that its investigational AK158D1, a next-generation EGFR/TROP2 bispecific antibody-drug conjugate...
Roche Lunsumio Regimen Improves PFS in Follicular Lymphoma
Basel, Switzerland, September 17, 2026 Roche has announced positive results from the Phase III CELESTIMO study, showing that a...
Advertisements
Disc Medicine Advances DISC-3405 in Polycythemia Vera
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
Cytek Biosciences Highlights Spectral Flow Cytometry at ESCCA
Fremont, California, USA — September 3, 2026 Cytek Biosciences, Inc. announced that it will showcase its spectral flow cytometry...
AbbVie Reports Positive Phase 3 Etentamig Results
North Chicago, Illinois, USA, September 3, 2026 AbbVie has announced positive topline results from the Phase 3 CERVINO trial,...
AN2 Therapeutics Highlights Epetraborole Data for PV at SOHO
MENLO PARK, Calif., August 31, 2026 AN2 Therapeutics, Inc. announced that four abstracts featuring clinical and translational data for...
Amarin Highlights New REDUCE-IT Data at ESC 2026
DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...
Advertisement
